Breast cancer metastasis to bone: Evolving models and research challenges

Journal of Musculoskeletal Neuronal Interactions

Volumn 3, Issue 1, 2003, Pages 30-38

  Welch, Danny R ^a,b,c,d   Harms, J F ^d   Mastro, A M ^b,f   Gay, C V ^b,f   Donahue, H J ^b,e  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d PENN STATE CANCER INSTITUTE   (United States)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

4T1; Adhesion; Chemokine; Green fluorescent protein; MDA MB 231; MDA MB 435; Organotropism; Osteoblast; Osteoclast; Osteolysis; Osteonectin; Osteopontin; Osteoprotegrin; PTHrP; RANK; RANK L

Indexed keywords

CHEMOKINE; GELATINASE A; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; SIALOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE METASTASIS; BREAST CANCER; CANCER GENETICS; CANCER RESEARCH; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HISTOLOGY; HOMEOSTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; REVIEW;

EID: 0037359909     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Sem Oncol 1996; 23:1-5.
2. Fremgen AM, Bland KI, McGinnis LS, Eyre HJ, McDonald CJ, Menck HR, Murphy GP. Clinical highlights from the National Cancer Data Base, 1999. CA Cancer J Clin 1999; 49:145-158.
3. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-1594.
4. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998; 34:240-245.
5. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18-54.
6. Rubens RD, Mundy GR. Cancer and the skeleton. London, Martin Dunitz, London; 2000.
7. Mundy GR. Mechanisms of bone metastasis. Cancer 1997; 80:1546-1556.
8. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571-573.
9. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55:3551-3557.
10. Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saffig P, Beertsen W. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 2002; 17:77-90.
11. Kubes P, Kerfoot SM. Leukocyte recruitment in the microcirculation: the rolling paradigm revisited. News Physiol Sci 2001; 16:76-80.
12. Mazo IB, Von Andrian UH. Adhesion and homing of blood-borne cells in bone marrow microvessels. J Leukoc Biol 1999; 66:25-32.
13. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance D. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000; 190:310-329.
14. Schnitzer JE, McKinstry P, Light TR, Ogden JA. Quantitation of regional chondro-osseous circulation in canine tibia and femur. Am J Physiol 1982; 242:H365-H375.
15. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380:364-366.
16. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and tumors. Ann Rev Immunol 2000; 18:813-827.
17. Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 1998; 47:295-302.
18. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, Von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med 1998; 188:465-474.
19. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: a multistep paradigm. Cell 1994; 76:301-314.
20. Murthy MS, Scanlon EF, Jelachich ML, Klipstein S, Goldschmidt RA. Growth and metastasis of human breast cancers in athymic nude mice. Clin Exp Metastasis 1995; 13:3-15.
21. Orr FW, Adamson IYR, Young L. Promotion of pulmonary metastases in mice by bleomycin-induced endothelial injury. Cancer Res 1986; 46:891-897.
22. Warren BA. The microinjury hypothesis and metastasis. Dev Oncol 1984; 22:56-61.
23. Ali S, Kaur J, Patel KD. Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 2000; 157:313-321.
24. Kam JL, Regimbald LH, Hilgers JHM, Hoffman P, Krantz MJ, Longenecker BM, Hugh JC. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res 1998; 58:5577-5581.
25. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996; 56:4244-4249.
26. Kramer RH, Nicolson GL. Interactions of tumor cells with vascular endothelial cell monolayers: a model for metastatic invasion. Proc Natl Acad Sci USA 1979; 76:5704-5708.
27. Goldblum SE, Ding X, Funk SE, Sage EH. SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. Proc Natl Acad Sci USA 1994; 91:3448-3452.
28. Carter WB, Hoying JB, Boswell C, Williams SK. HER2/neu over-expression induces endothelial cell retraction. Int J Cancer 2001; 91:295-299.
29. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999; 59:4453-4457.
30. Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1996; 1314:13-24.
31. Sung V, Stubbs JT III, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998; 176:482-494.
32. Orr W, Varani J, Gondex MK, Ward PA, Mundy GR. Chemotactic responses of tumor cells to products of resorbing bone. Science 1979; 203:176-179.
33. Gay CV, Mastro AM, Welch DR. Scanning electron microscopy reveals directional responses of breast cancer cells to osteonectin. J Bone Miner Res 2001; 16:S333.
34. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 1998; 58:5529-5536.
35. Shankavaram UT, DeWitt DL, Funk SE, Sage EH, Wahl LM. Regulation of human monocyte matrix metalloproteinases by SPARC. J Cell Physiol 1997; 173:327-334.
36. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7:1475-1482.
37. Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002; 277:9175-9182.
38. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochem Biophys Acta 2001; 1552:61-85.
39. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6:419-429.
40. Fisher LW, Whitson SW, Avioli LV, Termine JD. Matrix sialoprotein of developing bone. J Biol Chem 1983; 258:12723-12727.
41. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int 1991; 49:421-426.
42. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121-127.
43. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12:336-341.
44. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 1999; 72:209-253.
45. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62:1832-1837.
46. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-56.
47. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000; 88:2892-2898.
48. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79:243-253.
49. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000; 11:905-913.
50. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002; 20:795-823.
51. Thomas RJ, Guise TA, Yin JJ, Elliot J, Horwood NJ, Martin TJ, Gillespie MT. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140:4451-4458.
52. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-14367.
53. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001; 92:460-470.
54. Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, Fujiyama K, Kiriyama T, Aoyagi T, Maeda K, Eguchi K. Tumor necrosis factor-alpha and interleukin-1 beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999; 134:222-231.
55. Rouleau MF, Mitchell J, Goltzman D. In vivo distribution of parathyroid hormone receptors in bone: evidence that a predominant osseous target cell is not the mature osteoblast. Endocrinology 1988; 123:187-191.
56. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 2001; 16:1754-1764.
57. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103:197-206.
58. Gay CV, Zheng BZ, Gilman VR, Mastro AM. Immunolocalization of PTH receptors in osteoclasts of rat metaphyses. J Bone Miner Res 2001; 16:S425.
59. Faucheux C, Horton MA, Price JS. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. J Bone Miner Res 2002; 17:455-464.
60. Gay CV, Weber JA. Regulation of differentiated osteoclasts. Crit Rev Eukaryot Gene Expr 2000; 10:213-230.
61. Sanchez-Sweatman OH, Orr FW, Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998; 18:297-305.
62. Sanchez-Sweatman OH, Lee J, Orr FW, Singh G. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur J Cancer 1997; 33:918-925.
63. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-137.
64. Mastro AM, Gay CV, Welch DR, Donahue HJ, Jewell J. A role for osteoblast apoptosis in breast cancer osteolytic metastasis? Proc Amer Assoc for Cancer Res 2002; 43:1570.
65. Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE, Baron R. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982; 55:219-227.
66. Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exptl Metastasis 1997; 15:272-306.
67. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exptl Metastasis 1999; 17:163-170.
68. Clarke R. Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research. Breast Cancer Res Treat 1997; 46:117-133.
69. Davies MPA, Rudland PS, Robertson L, Parry EW, Jolicoeur P, Barraclough R. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV- neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996; 13:1631-1637.
70. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nature Med 2000; 6:306-312.
71. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998; 95:14417-14422.
72. LeVoyer T, Lifsted T, Williams M, Hunter K. Identification and mapping of a mammary tumor metastasis susceptibility gene. U.S. Army Med Res & Material Command Era of Hope Meeting 2, 625; 2000.
73. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000; 19:1002-1009.
74. Maglione JE, Moghanaki D, Young LJT, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001; 61:8298-8305.
75. Zhang M, Shi Y, Magit D, Furth PA, Sager R. Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene 2000; 19:6053-6058.
76. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876-6881.
77. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16:1486-1495.
78. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994; 32:73-84.
79. Harms JF, Welch DR. MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 2003; (in press).
80. Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000; 60:2764-2769.
81. Samant RS, Seraj MJ, Welch DR. Breast carcinoma metastasis suppressor, BRMS1. Cancer Research Alert 2000; 2:57-59.
82. Samant RS, Debies MT, Shevde LA, Welch DR. Identification and characterization of mouse homolog (Brms1) of the breast cancer metastasis suppressor BRMS1. Proc Amer Assoc for Cancer Res 2001; 42:2808.
83. Shevde LA, Samant RS, Welch DR. Suppression of human melanoma metastasis by breast metastasis suppressor [BRMS1]. Proc Amer Assoc for Cancer Res 2001; 42:646.
84. Lee J-H, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996; 88:1731-1737.
85. Lee J-H, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997; 57:2384-2387.
86. Miele ME, Gresham VC, Stanbridge EJ, Weissman BE, Welch DR. Metastasis, but not tumorigenicity, is suppressed and nm23 levels are increased by introduction of chromosome 6 into human malignant melanoma cell line C8161. Proc Amer Assoc for Cancer Res 1994; 35:325.
87. Welch DR, Chen P, Miele ME, McGary CT, Bower JM, Weissman BE, Stanbridge EJ. Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 1994; 9:255-262.
88. Goldberg SF, Harms JF, Quon K, Welch DR. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis 1999; 17:601-607.
89. Yoshida BA, Dubauskas Z, Chekmareva MA, Zaucha MM, Christiano TR, Christiano AP, Stadler WM, Rinker-Schaeffer CW. Identification and characterization of candidate prostate cancer metastasis-suppressor genes encoded on human chromosome 17. Cancer Res 1999; 59:5483-5487.
90. Rinker-Schaeffer CW, Welch DR, Sokoloff M. Defining the biologic role of genes that regulate prostate cancer metastasis. Curr Opin Urol 2001; 10:397-401.
91. Yoshida BA, Sokoloff M, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 2000; 92:1717-1730.
92. Freije JM, MacDonald NJ, Steeg PS. Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 1998; 63:261-271.
93. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, Groom AC. Steps in tumor metastasis: New concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995; 14:279-301.
94. Koop S, MacDonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, Khokha R, Chambers AF, Groom AC. Fate of melanoma cells entering the microcirculation: Over 80% survive and extravasate. Cancer Res 1995; 55:2520-2523.
95. Saunders MM, Seraj MJ, Li ZY, Zhou ZY, Winter CR, Welch DR, Donahue HJ. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001; 61:1765-1767.
96. Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, Mauger DT, Welch DR. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002; 273:229-239.